Skip to main content
. Author manuscript; available in PMC: 2017 Sep 18.
Published in final edited form as: Amyloid. 2011 Jun;18(Suppl 1):127–129. doi: 10.3109/13506129.2011.574354047

Figure 2.

Figure 2

Overall and event-free survival for 323 patients based upon intention-to-treat. The median overall survival was 7.7 years (95% CI: 69–120 months) and the event-free survival was 4.2 years (95% CI: 36–69 months).